1
|
Ju MH, Byun KD, Park EH, Lee JH, Han SH. Association of Galectin 9 Expression with Immune Cell Infiltration, Programmed Cell Death Ligand-1 Expression, and Patient's Clinical Outcome in Triple-Negative Breast Cancer. Biomedicines 2021; 9:biomedicines9101383. [PMID: 34680500 PMCID: PMC8533056 DOI: 10.3390/biomedicines9101383] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/28/2021] [Accepted: 09/29/2021] [Indexed: 01/03/2023] Open
Abstract
Galectin-9 (Gal-9) is an immune checkpoint protein that facilitates T cell exhaustion and modulates the tumor-associated microenvironment, and could be a potential target for immune checkpoint inhibition. This study was conducted to assess Gal-9 expression in triple-negative breast cancer (TNBC) and evaluate its association with programmed cell death ligand 1 (PD-L1) expression and immune cell infiltration in tumors and the clinical outcome of patients. Overall, 109 patients with TNBC were included. Gal-9 expression was assessed its relationships with tumor clinicopathologic characteristics, tumor-infiltrating lymphocyte (TIL) levels, PD-L1+ immune cells, and tumor cells by tissue microarray and immunohistochemistry. Low Gal-9 expression was statistically correlated with higher tumor stage (p = 0.031) and presence of lymphovascular invasion (p = 0.008). High Gal-9 expression was associated with a high level of stromal TILs (sTIL; p = 0.011) and positive PD-L1 expression on tumor cells (p = 0.004). In survival analyses, low Gal-9 expression was associated with significantly poor OS (p = 0.013) in patients with TNBC with PD-L1 negativity in tumor cells. Our findings suggest that increased Gal-9 expression is associated with changes in the antitumor microenvironment, such as increased immune cell infiltration and antimetastatic changes. This study emphasizes the predictive value and promising clinical applications of Gal-9 in TNBC.
Collapse
Affiliation(s)
- Mi-Ha Ju
- Department of Pathology, Dong-A University College of Medicine, Busan 49201, Korea;
| | - Kyung-Do Byun
- Department of Surgery, Dong-A University Hospital, Dong-A University College of Medicine, Busan 49201, Korea; (K.-D.B.); (E.-H.P.)
| | - Eun-Hwa Park
- Department of Surgery, Dong-A University Hospital, Dong-A University College of Medicine, Busan 49201, Korea; (K.-D.B.); (E.-H.P.)
| | - Jin-Hwa Lee
- Department of Radiology, Dong-A University Hospital, Dong-A University College of Medicine, Busan 49201, Korea;
| | - Song-Hee Han
- Department of Pathology, Dong-A University College of Medicine, Busan 49201, Korea;
- Correspondence: ; Tel.: +82-51-240-5353
| |
Collapse
|
2
|
Yun SH, Sim EH, Han SH, Kim TR, Ju MH, Han JY, Jeong JS, Kim SH, Silchenko AS, Stonik VA, Park JI. In vitro and in vivo anti-leukemic effects of cladoloside C 2 are mediated by activation of Fas/ceramide synthase 6/p38 kinase/c-Jun NH 2-terminal kinase/caspase-8. Oncotarget 2017; 9:495-511. [PMID: 29416631 PMCID: PMC5787484 DOI: 10.18632/oncotarget.23069] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 11/14/2017] [Indexed: 11/25/2022] Open
Abstract
We previously demonstrated that the quinovose-containing hexaoside stichoposide C (STC) is a more potent anti-leukemic agent than the glucose-containing stichoposide D (STD), and that these substances have different molecular mechanisms of action. In the present study, we investigated the novel marine triterpene glycoside cladoloside C2 from Cladolabes schmeltzii, which has the same carbohydrate moiety as STC. We assessed whether cladoloside C2 could induce apoptosis in K562 and HL-60 cells. We also evaluated whether it showed antitumor action in mouse leukemia xenograft models, and its molecular mechanisms of action. We investigated the molecular mechanism behind cladoloside C2-induced apoptosis of human leukemia cells, and examined the antitumor effect of cladoloside C2 in a HL-60 and K562 leukemia xenograft model. Cladoloside C2 dose- and time-dependently induced apoptosis in the analyzed cells, and led to the activation of Fas/ceramide synthase 6 (CerS6)/p38 kinase/JNK/caspase-8. This cladoloside C2-induced apoptosis was partially blocked by specific inhibition by Fas, CerS6, and p38 siRNA transfection, and by specific inhibition of JNK by SP600125 or dominant negative-JNK transfection. Cladoloside C2 exerted antitumor activity through the activation of Fas/CerS6/p38 kinase/JNK/caspase-8 without showing any toxicity in xenograft mouse models. The antitumor effect of cladoloside C2 was reversed in CerS6 shRNA-silenced xenograft models. Our results suggest that cladoloside C2 has in vitro and in vivo anti-leukemic effects due to the activation of Fas/CerS6/p38 kinase/JNK/caspase-8 in lipid rafts. These findings support the therapeutic relevance of cladoloside C2 in the treatment of human leukemia.
Collapse
Affiliation(s)
- Seong-Hoon Yun
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| | - Eun-Hye Sim
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| | - Sang-Heum Han
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| | - Tae-Rang Kim
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| | - Mi-Ha Ju
- Department of Pathology, Dong-A University College of Medicine, Busan, South Korea
| | - Jin-Yeong Han
- Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, South Korea
| | - Jin-Sook Jeong
- Department of Pathology, Dong-A University College of Medicine, Busan, South Korea
| | - Sung-Hyun Kim
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea
| | - Alexandra S Silchenko
- G.B. Elyakov Pacific Institute of Bio-organic Chemistry, Far-Eastern Branch of the Russian Academy of Sciences, Vladivostok, Russia
| | - Valentin A Stonik
- G.B. Elyakov Pacific Institute of Bio-organic Chemistry, Far-Eastern Branch of the Russian Academy of Sciences, Vladivostok, Russia
| | - Joo-In Park
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| |
Collapse
|
3
|
Kim CH, Ju MH, Kim BJ. Comparison of recombinant human bone morphogenetic protein-2-infused absorbable collagen sponge, recombinant human bone morphogenetic protein-2-coated tricalcium phosphate, and platelet-rich fibrin-mixed tricalcium phosphate for sinus augmentation in rabbits. J Dent Sci 2017; 12:205-212. [PMID: 30895052 PMCID: PMC6400000 DOI: 10.1016/j.jds.2017.01.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Revised: 01/09/2017] [Accepted: 01/10/2017] [Indexed: 11/02/2022] Open
Abstract
Background/purpose Numerous grafting materials have been used in the bone regeneration of maxillary sinus to obtain a sufficient amount of new bone in implant dentistry. The objective of this study was to compare the potentials of Type I absorbable collagen sponge (ACS) impregnated with recombinant human bone morphogenetic protein (rhBMP)-2, rhBMP-2-coated tricalcium phosphate (TCP), platelet-rich fibrin-mixed TCP for enhancing bone regeneration in sinus augmentation in rabbits. Materials and methods The sinus defects were grafted with rhBMP-2+ACS (Group A), rhBMP-2-coated TCP (Group B), and platelet-rich fibrin-mixed TCP (Group C). The specimens underwent decalcification, and were stained for histomorphometric analysis. Results There were no significant differences in inflammatory features among the groups 1-week postoperation. In a histomorphometric analysis, the new bone formation ratio showed significant differences between groups at 2 weeks. rhBMP-2+ACS showed a larger and more rapid bone formation area at 2 weeks than those of Groups B and C. Conclusion Our histological evaluation demonstrates that Type I ACS can be used as a carrier of rhBMP-2, and rhBMP-2+ACS showed rapid bone formation, remodeling, and calcification at Week 2 in rabbit.
Collapse
Affiliation(s)
- Chul-Hun Kim
- Department of Oral and Maxillofacial Surgery, Assistant Professor, Dong-a Univ. College of Medicine, Busan, South Korea
| | - Mi-Ha Ju
- Department of Pathology, Faculty of Pathology, Dong-a University College of Medicine, Busan, South Korea
| | - Bok-Joo Kim
- Department of Oral and Maxillofacial Surgery, Assistant Professor, Dong-a Univ. College of Medicine, Busan, South Korea
| |
Collapse
|
4
|
Yun SH, Park ES, Shin SW, Ju MH, Han JY, Jeong JS, Kim SH, Stonik VA, Kwak JY, Park JI. By activating Fas/ceramide synthase 6/p38 kinase in lipid rafts, stichoposide D inhibits growth of leukemia xenografts. Oncotarget 2016; 6:27596-612. [PMID: 26318294 PMCID: PMC4695011 DOI: 10.18632/oncotarget.4820] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Accepted: 07/17/2015] [Indexed: 01/20/2023] Open
Abstract
Stichoposide D (STD) is a marine triterpene glycoside isolated from sea cucumbers. We examined the molecular mechanisms underlying the antitumor activity of STD in human leukemia cells. The role of Fas (CD95), ceramide synthase 6 (CerS6) and p38 kinase during STD-induced apoptosis was examined in human leukemia cells. In addition, the antitumor effects of STD in K562 and HL-60 leukemia xenograft models were investigated. We found that STD induces Fas translocation to lipid rafts, and thus mediates cell apoptosis. We also observed the activation of CerS6 and p38 kinase during STD-induced apoptosis. The use of methyl-β-cyclodextrin and nystatin to disrupt lipid rafts prevents the clustering of Fas and the activation of CerS6 and p38 kinase, and also inhibits STD-induced apoptosis. Specific inhibition by Fas, CerS6, and p38 kinase siRNA transfection partially blocked STD-induced apoptosis. In addition, STD has antitumor activity through the activation of CerS6 and p38 kinase without displaying any toxicity in HL-60 and K562 xenograft models. We observed that the anti-tumor effect of STD is partially prevented in CerS6 shRNA-silenced xenograft models. We first report that Fas/CerS6/p38 kinase activation in lipid rafts by STD is involved in its anti-leukemic activity. We also established that STD is able to enhance the chemosensitivity of K562 cells to etoposide or Ara-C. These data suggest that STD may be used alone or in combination with other chemotherapeutic agents to treat leukemia.
Collapse
Affiliation(s)
- Seong-Hoon Yun
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| | - Eun-Seon Park
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| | - Sung-Won Shin
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| | - Mi-Ha Ju
- Department of Pathology, Dong-A University College of Medicine, Busan, South Korea
| | - Jin-Yeong Han
- Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, South Korea
| | - Jin-Sook Jeong
- Department of Pathology, Dong-A University College of Medicine, Busan, South Korea
| | - Sung-Hyun Kim
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea
| | - Valentin A Stonik
- G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far East Division, The Russian Academy of Sciences, Vladivostok, Russia
| | - Jong-Young Kwak
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| | - Joo-In Park
- Department of Biochemistry, Dong-A University College of Medicine, Busan, South Korea
| |
Collapse
|
5
|
Ju MH, Rodríguez HE. Standard balloon angioplasty versus angioplasty with paclitaxel-eluting balloons for femoropopliteal artery stenosis. J Cardiovasc Surg (Torino) 2012; 53:459-463. [PMID: 22854525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM The aim of this article was to review the available literature on the use of drug-coated balloons (DCB) for endovascular treatment of femoropopliteal arterial stenosis. METHODS Manual searches of articles, presentations, and clinical trials were performed. Selected references were reviewed and summarized. RESULTS Due to the high morbidity associated with femoropopliteal bypass, endovascular approaches, such as balloon angioplasty and stent placement, have become the first line of therapy for isolated, de novo femoral atherosclerosis. However, percutaneous interventions have been limited by restenosis. In an effort to overcome this obstacle, the use of antiproproliferative drugs to inhibit hyperplasia has been attempted. The success of drug-eluting stents (DES) in the coronary circulation has not been reproduced in the femoropopliteal segment. Animal and human experiments have shown prolonged inhibition of intimal hyperplasia with single delivery of large doses of paclitaxel during balloon angioplasty. Recent randomized trials have shown significant advantages at 12 and 24 month angiographic follow-up with the use of DCB when compared to standard balloon angioplasty. CONCLUSION Several clinical trials have demonstrated promising early results with the use of DCB in treating femoropopliteal stenosis. However, long term results, exact indications, and optimal applications are yet to be determined.
Collapse
Affiliation(s)
- M H Ju
- Division of Vascular Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60661, USA
| | | |
Collapse
|
6
|
Jin SB, Ju MH. [Case report of bronchial aspiration of metal casting during dental treatment]. Taehan Chikkwa Uisa Hyophoe Chi 1989; 27:965-8. [PMID: 2489617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The authors experienced the bronchial aspiration of metal crown during dental treatment. This article discussed prevention and management of this event. The following conclusions were obtained from this study. 1. The preventive measures such as pharyngeal screen must be used in insertion and removal of metal casting. 2. The patient should be informed of this event before treatment. 3. If prosthesis was disappeared in oral cavity during dental treatment, a dentist must consult the radiologist for diagnostic x-ray taking, even though patient has no symptoms suggestive of aspiration of foreign body. 4. If expulsion of a prosthesis from the airway is not occurred, consultation to the ENT for bronchoscopy should be accompanied.
Collapse
|